课题基金 / 基金详情

Academic Leadership Award at the Indiana University School of Medicine

Academic Leadership Award at the Indiana University School of Medicine
印第安纳大学医学院学术领导奖
批准号:
9892249
负责人:
GARY E. LANDRETH
金额:
$16.19万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-01-01 至 2024-12-31

项目摘要

项目成果

GARY E. LANDRETH的其他基金

相关文献

中文摘要
翻译
主要调查者:加里·E·兰德雷思 项目摘要/摘要 本次学术领袖奖的申请是针对协调发展和 印第安纳大学关于老龄化、阿尔茨海默病和相关痴呆症的综合教育计划 大学医学院(IUSM)主要目标是提供一个组织框架,固定在 医学神经科学培训计划,将现有活动与发展活动进行功能整合 NIA为IUSM提供了资源支持。NIA支持印第安纳州阿尔茨海默病研究中心, 阿尔茨海默病国家细胞库、雷根斯特里夫研究所和老龄中心 研究以及最近资助的模型-AD中心和领导临床试验。最后,礼来公司是 总部设在印第安纳波利斯,在阿尔茨海默氏症方面有大量的研究工作。这些 机构包括独特而重要的智力和基础设施资源,将在 目前的提案。 IUSM和NIA最近投入了大量的机构资源来开发基本的 对阿尔茨海默病和神经退行性疾病的科学研究。然而,调查的成功 努力将取决于提供一支熟练的劳动力。本申请描述了一种计划 利用医学神经科学培训计划作为工具来加强和协调研究和 国际理论物理联合会的培训活动。培训方案将同时加强和扩大机构 通过在个人研究中向教职员工提供一批有才华的年轻研究人员来提高研究能力 中心,并为这些人提供高水平的培训。重要的是,培训的活动 该计划提供了一种机制,以促进教师和研究人员之间的互动和合作 IUSM和礼来公司从事衰老和神经退行性疾病研究的工作人员。 申请者Gary Landreth博士应聘到IUSM领导发展和重组 医学神经科学培训计划。他为这项工作带来了30年的阿尔茨海默氏症经验 疾病研究和研究生教育。 申请的具体目标是:1)重组医学神经科学培训计划 通过a)使研究生课程现代化,以提供神经科学、老龄化方面的基础培训 和神经退行性疾病,b)启动博士后培训方案,以促进专业人员 促进这一科学劳动力的重要组成部分,以及c)提供本科生研究 经历。2)利用医学神经科学培训计划作为整合活动的载体 在各种IUSM中心中,重点关注衰老和神经退行性疾病。3)促进翻译 通过医学神经科学培训计划与礼来公司的研究互动。
英文摘要
Principal Investigator: Landreth, Gary E Project Summary/Abstract This academic leadership award application is directed at the development of coordinated and comprehensive educational programs in aging, Alzheimer’s disease and related dementias at the Indiana University School of Medicine (IUSM). A primary goal is to provide an organizational framework, anchored in the Medical Neurosciences Training Program, to functionally integrate the activities of existing and developing NIA supported resources at the IUSM. The NIA supports the Indiana Alzheimer’s Disease Research Center, the National Cell Repository for Alzheimer’s Disease, the Regenstrief Institute and the Center for Aging Research as well as the recently funded MODEL-AD center and LEADS clinical trial. Finally, Eli Lilly is headquartered in Indianapolis and has a substantial research effort focused on Alzheimer’s disease. These institutions comprise a unique and significant intellectual and infrastructural resource that will be leveraged in the current proposal. The IUSM and the NIA have recently committed substantial institutional resources to develop basic science research efforts on AD and neurodegenerative diseases. However, the success of the investigative effort will be contingent upon provision of a skilled workforce. The present application describes a plan to employ the Medical Neuroscience Training program as a vehicle to enhance and coordinate the research and training activities at the IUSM. The training program will simultaneously enhance and expand the institutional research capacity by providing a talented pool of young investigators to faculty within the individual research centers, and provide a high level training for these individuals. Importantly, the activities of the training program provide a mechanism to promote interactions and collaborations between the faculty and research staff at IUSM and Lilly who work on aging and neurodegenerative diseases. The applicant, Dr. Gary Landreth, was recruited to IUSM to lead the development and restructuring of the Medical Neurosciences Training Program. He brings to this effort 30 years of experience in Alzheimer’s disease research and graduate education. The Specific Aims of the application are:1) To restructure the Medical Neuroscience Training program through a) modernizing the graduate curriculum to provide foundational training in the Neurosciences, aging and neurodegenerative diseases, b) initiation of a postdoctoral training program to promote the professional advancement of this important component of the scientific workforce and c) provide undergraduate research experiences. 2) To employ the Medical Neuroscience Training Program as a vehicle to integrate the activities of the various IUSM centers focused on Aging and Neurodegenerative diseases. 3) To promote translational research interactions through the Medical Neuroscience Training Program with Eli Lilly.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repurposing FDA-approved agonists of HCAR2 as novel therapeutics for Alzheimer's Disease
Training Grant on Alzheimer's Disease and ADRD at Indiana University
Training Grant on Alzheimer's Disease and ADRD at Indiana University
Training Grant on Alzheimer's Disease and ADRD at Indiana University